Novavax, Inc. splits its revenue into 3 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Licensing Royalties And Other at $42.6 million, 62% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
412
|
68
|
57
|
140
|
147
|
70
|
239
|
667
|
88
|
| Licensing Royalties And Other |
286
-20.5%
share 69.4%
|
43
-25.3%
share 62.4%
|
38
-83.4%
share 66.7%
|
97
+116.4%
share 69.8%
|
108
+180.1%
share 73.4%
|
57
share 80.9%
|
229
share 95.5%
|
45
share 6.7%
|
39
share 43.6%
|
| Product |
126
-82.1%
share 30.6%
|
26
+91.1%
share 37.6%
|
19
+75.8%
share 33.3%
|
42
-93.2%
share 30.2%
|
39
-21.3%
share 26.6%
|
13
share 19.1%
|
11
share 4.5%
|
622
share 93.3%
|
50
share 56.4%
|
| Nuvaxovid Sales |
—
|
—
|
—
|
10
-98.4%
share 6.9%
|
20
-60.7%
share 13.3%
|
-0
share -0.5%
|
-2
share -0.9%
|
608
share 91.2%
|
50
share 56.4%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- NVAX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Gaithersburg, MD
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1000694
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.